Purpose After reports of malaise in infants immediately after the oral administration of two brands of vitamin D solutions, a "Dear Doctor letter" (DDL) containing recommendations for the administration of vitamin D was sent to all French paediatricians and pharmacies and a large number of French general practitioners (GPs) with a predominantly paediatric practice. The DDL and a press release were published on the French Medicines Agency website and distributed via a mailing list. The objective of this study was to assess the effectiveness of such a DDL and to collect the opinions of healthcare professionals on the best way to provide them with information. Methods A questionnaire was sent to a national random sample of 145 paediatricians, 680 GPs and 230 pharmacists.
Introduction
The occurrence of an adverse drug reaction (ADR) is, in most cases, due to the nature of the active ingredient(s) and/ or to the characteristics of the patient. In some cases, however, neither the medicine itself nor the patient's characteristics are actually the cause of the ADR-rather the cause is related to the pattern of drug administration. In 2006, spontaneous reports to the French pharmacovigilance system of malaise in neonates and infants caused a safety concern related to an incorrect method of medicine administration and to a pipette not adapted for neonates. These malaises occurred immediately after the administration of two brands of an oral solution of vitamin D, the first alone and the second in combination with vitamins A, E and C. A too rapid administration directly to the oropharynx was the likely cause of these vagal malaises. In accordance with common practice in Europe and elsewhere in cases of reported risks related to the use of a specific medicine [1, 2] , the manufacturer concerned, at the request of the French Medicines Agency (AFSSAPS for Agence Française de Sécurité Sanitaire des Produits de Santé), sent a "Dear Doctor Letter" (DDL) to all French paediatricians (n=5,290) and pharmacies (n= 22,610) and to many of those general practitioners (GPs) believed to have a predominantly paediatric practice (n= 553; i.e. 0.9% of the 62,994 GPs in France). The purpose of the DDL was to issue recommendations on the use of these solutions and to notify the relevant healthcare professionals that a new pipette aimed at reducing this risk would shortly be made available [3] . The AFSSAPS placed a press release, the standard practice in such a case, on its website on October 19, 2006 [4] , which was relayed by the French Medical Press Agency for dissemination in the media. An e-mail with a link to the press release and the DDL were also sent to the subscribers of the AFSSAPS mailing list, to which anyone may freely subscribe.
The number of such DDLs issued has increased over time [5] [6] [7] (Fig. 1) . Within the context of modern communication methods, which have become highly diverse and increasingly sophisticated in recent years, we wished to assess the effectiveness of this strategy of DDLs and to collect the opinions of physicians and pharmacists on the most adequate methods to convey important information to healthcare professional.
Methods

Study design
A cross-sectional survey was conducted among a national random sample of 145 paediatricians (poll rate: 1/36), 680 general practitioners (poll rate: 1/93) and 230 pharmacies (poll rate: 1/98) in community settings. The random sample of healthcare professionals was obtained from listings of professional bodies with a stratification by administrative region: private practice paediatricians, private practice GPs and owners of community pharmacies.
Data collection
Physicians and pharmacists were asked to complete a postal questionnaire in order to evaluate if they were aware of and followed new recommendations for the administration of the vitamin formulations concerned. The following questions were asked: (1) Are you aware of the new recommendations for the administration of these solutions? (2) Have you changed your prescribing behaviour (for paediatricians and GPs)/dispensation (for pharmacists) patterns? (3) Do you (for paediatricians and GPs) prescribe these vitamin brands? (4) What is your opinion regarding the most effective ways to issue a drug safety warning? For the latter question, we chose to use an open-ended question so as to not influence the replies of the respondents. To minimize a possible selection bias, we chose to use anonymous pre-paid envelopes for the return of the questionnaires so that healthcare professionals would feel free to complete the questionnaire and to limit the possibility of spurious replies.
Analysis
Data were analyzed using STATA software ver. 8.2 for Macintosh (STATA Corp, College Station, TX). 
Results
The response rates for paediatricians, GPs and pharmacists were 31 (n=45), 37 (n=255) and 40% (n=92), respectively.
Knowledge of the new information and change in prescribing behaviour
Paediatricians
Of the 45 responding paediatricians, 49% (22/45) knew of the recommendations and 67% (30/45) prescribed the vitamin brands concerned (Table 1) . Among the 16 paediatricians who were both informed and prescribed these vitamins, 50% (8/16) stated to have changed their prescribing behaviour and/or advice to families and 50% (8/ 16) reported not to have modified their explanations when prescribing the solutions.
General practitioners
Of the 255 responding GPs, 48% (122/255) knew of the recommendations and 50% (127/255) prescribed the vitamin brands concerned (Table 1) . Among the 68 GPs who were both informed and prescribed these vitamins, 68% (46/68) stated that they had changed their prescribing behaviour and/or advice to families, 29% (20/68) replied that they had not modified their explanations when prescribing (two had issued explanations on the administration of the vitamins similar to that contained in the DDL, before the alert) and 3% (2/68) did not know whether they had modified their explanations.
Pharmacists
Among the 92 responding pharmacists, 67% (62/92) knew of the recommendations (Table 1) . Of these, 68% (42/62) replied that they had changed their advice when dispensing, 18% (11/62) stated that they had not modified their explanations and 14% (9/62) stated that they had not sold the vitamin brands concerned since the recommendations were issued.
Of the healthcare professions who returned a completed questionnaire, 50% of paediatricians and 68% of GPs and pharmacists replied that they were both affected by the recommendations and had changed their prescribing behaviour.
Opinions on the most effective ways to issue a drug safety warning According to the participating paediatricians, GPs and pharmacists, a postal letter remains the best way to disseminate a safety warning (42%), followed by e-mail/ Internet (25%).
Several proposals emerged from their replies that could improve the issuing of drug safety warnings: special envelope (e.g. yellow envelope) for all DDLs; specific pictogram on all envelopes and letters for safety warnings; alert information in prescription or dispensing software updates; warning stickers on medicine boxes; involvement in issuing of new recommendations of other major stakeholders in the healthcare system, such as professional associations, pharmacovigilance centres and, for pharmacists, wholesale distributors.
Discussion
The answers to our survey confirm that the current strategy commonly used in Europe to issue safety warnings on drug use, which consists of sending a DDL to healthcare professionals and disseminating the information via an Agency website, is not a priori sufficient to satisfactorily change prescription/dispensation patterns. A similarly poor impact of communication strategies has been reported in earlier published studies [8] [9] [10] [11] [12] [13] [14] , but our study goes further than previous ones by illustrating the limited capacity of such a strategy to provide information to healthcare professionals. The difficulty in the case presented here was to disseminate a safety warning for medicines systematically prescribed to all infants and young children but which were also available without prescription and more often perceived as vitamin supplements than as Data are presented as the number (n), with the percentage of each group given in parenthesis medicines by the general public. Indeed, the safety warning was sent to all paediatricians and pharmacists, but only 49-67% of these declared being aware of the alert. Surprisingly, GPs were aware of the alert to the same extent as the other healthcare professionals despite the DDL having been sent only to a small minority of them (<1%). This finding could suggest that the GPs in this study responded that they were aware of the information in DDLs without actually being so, but that would be surprising that GPs provided more inaccurate replies than paediatricians and pharmacists. The alternative may be that GPs had picked up information via another source than the DDL, which again suggests a poor effectiveness of the DDL. Another relevant result is the relatively high proportion of healthcare professionals who knew of the recommendations for the administration of these solutions but who did not change their prescribing behaviour (30-50%). One explanation for this lack of any change in prescribing behaviour given by some health professionals was that there was no need to do so as a new pipette would soon be available (data not shown). These points highlight the difficulty in composing a message that will be unequivocally understood when many, often conflicting, viewpoints coexist; they also argue for a critical review and analysis of the DDLs by a panel of the intended recipients and by psychologists [15] . However, despite the limited effectiveness of the DDL to convey information, the responding health professionals considered the postal letter to be the best way to issue a safety warning. Some responders suggested that a better identification of the DDL with, for example, a specific envelope and/or pictogram, could improve its effect. A greater dissemination of the DDL using a postal letter combined with other means of communication could be of great benefit by reaching more people [16] [17] [18] . In our study, some healthcare professionals suggested using e-mail, which has the advantage of issuing the information immediately to a large population [19] . This way of communication is available through the French Medicines Agency website and is used by around 20,000 subscribers; it should therefore be publicized to maximize the number of subscribers to this mailing list. The involvement of other healthcare professionals, such as pharmacy wholesalers, professional medical associations and/or pharmacovigilance centres, which would then communicate the DDL to the concerned healthcare professionals, could also be a worthwhile approach as it could increase dissemination of the DDL [20, 21] . The participation of wholesalers, in particular by distributing the DDL along with medicines, could significantly improve the issuing of a warning; this practice is now recommended in the 2008 issue of volume 9A of pharmacovigilance guidelines in Europe [20] . Improving the line of communication with pharmacists is essential in such campaigns [8, [22] [23] [24] [25] , as pharmacists are the last in the chain to deliver information and have an overall view of each patient's treatment, including self-medication.
However, in the case described here, which concerns recommendations for the administration of paediatric medicines that are available without prescription, a measure that would be both easy to implement and highly effective is the application of stickers on medicine boxes. This means of communication, in accordance with the proposals of the European Medicines Agency [26] , presents the indisputable advantages of delivering the information to the patient at the time when pharmacists need it to be delivered and to promote an active discussion between the pharmacist and the patient. Also, in contrast to the other measures proposed, applying stickers to medicine boxes has the additional advantage of directly reaching the concerned population [27, 28] ; in the current case, this would not be the physicians or the pharmacists, but the parents. Another way to issue the recommendations directly to the parents could have been to launch a general information campaign on liquid administration to babies through specialized magazines.
Limitations
For confidentiality reasons and in accordance to the French law on data protection [29] , the manufacturer concerned did not provide us with the addresses of the healthcare professionals receiving the DDL. This could have jeopardized the study results if the questionnaire had been sent to heathcare professionals not targeted for the DDL mailing. This questionnaire was actually sent to healthcare professionals currently registered in their respective professional body i.e. professionally active; as such they comprised the target population for conveying information about the new recommendations for vitamin D administration.
The participation rates for paediatricians (31%), GPs (37%) and pharmacists (40%) could be qualified as low; however, they are in agreement with those found in other published studies using neither follow-up nor fee [30, 31] . Nevertheless, given this limited number of participating paediatricians and pharmacists, generalization of the poor effectiveness of the DDL to the whole source population could be questioned. However, the poor assessment of the usefulness of the DDL by both paediatricians and pharmacists provides more support to the results. Furthermore, the finding that the GPs knew of the new recommendations on vitamin D administration to the same order of magnitude as the paediatricians and pharmacists, even though relatively few GPs were targeted for the DDL mailing, reinforces the conclusion on the limited effectiveness of such a warning issued by DDL.
Finally, the rate of heathcare professionals replying that they were aware of the recommendations for vitamin D administration and subsequently changed their prescribing behaviour is more likely, if biased, to be overestimated rather than underestimated. Indeed, those who had paid attention to the DDL were probably more prone to spend time to filling in questionnaires on drug safety. Moreover, this possible overrepresentation in the study sample of healthcare professionals having paid attention to their postal mail could have inflated the proportion of those giving preference for being informed by postal letter. However, it is unlikely that this could alter the proportion of healthcare professionals favouring information through e-mail/Internet since the question referring to the most effective ways to convey a drug safety warning was open-ended.
Conclusions
The results of this study suggest that the healthcare professionals who completed and returned the questionnaire paid little attention to the DDL and were therefore unlikely to markedly change their prescribing practices. Improvements could be made by a better identification of the DDL using a special envelope and a specific pictogram and by a widening dissemination of the information to other stakeholders involved in the healthcare system. In the case presented here, a relevant measure to disseminate recommendations for drug administration could consist in applying stickers on medicine boxes, as this approach has the major advantage of providing the population concerned, i.e. the parents, with the relevant information.
